№ files_lp_3_process_7_056723
File format: docx Character count: 70612 File size: 129 KB
Year: 2021
Region / City: Australia
Subject: Chronic Obstructive Pulmonary Disease (COPD)
Document Type: Application for PBS Listing Amendment
Organization: GlaxoSmithKline
Author: Not specified
Target Audience: Medical Practitioners, Healthcare Professionals
Period of Effect: Not specified
Approval Date: Not specified
Modification Date: Not specified
Requested Action: Removal of clinical criteria in PBS listing for Trelegy
Clinical Focus: Treatment of moderate to severe COPD
Intervention: Trelegy inhalation therapy (ICS/LAMA/LABA combination)
Comparator: Dual therapy LAMA/LABA
Outcomes: Reduction in COPD exacerbations, improvement in lung function
Indication: Chronic Obstructive Pulmonary Disease (COPD)
Restriction: Authority required, restricted benefit
Administrative Notes: Emphasis on correct inhaler technique, spirometry requirement for COPD diagnosis
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Fluticasone furoate with umeclidinium and vilanterol for severe asthma: 24 month predicted versus actual analysis
Year: 2025
Region / city: Australia
Topic: Severe asthma treatment and medication analysis
Document type: Report
Organization: Drug Utilisation Sub-committee (DUSC)
Author: Unknown
Target audience: Healthcare professionals, policymakers
Period of validity: April 2025
Date of approval: Not mentioned
Date of changes: Not mentioned
Fluticasone furoate with umeclidinium and vilanterol for severe asthma: 24 month predicted versus actual analysis
Year: 2025
Region / city: Australia
Topic: Severe asthma treatment and medication analysis
Document type: Report
Organization: Drug Utilisation Sub-committee (DUSC)
Author: Unknown
Target audience: Healthcare professionals, policymakers
Period of validity: April 2025
Date of approval: Not mentioned
Date of changes: Not mentioned
Traffic Signal Controller and Cabinet, Fully Actuated 8-Phase, Item SPV.0060.###.A Description
Note: Year
Topics: Umeclidinium Vilanterol Actuated